Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(17%)
Results Posted
100%(3 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
4
67%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

terminated233%
active_not_recruiting117%
completed350%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingphase_1

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

NCT03333343
terminatedphase_2

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

NCT03292133
completedphase_1

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

NCT02108964
completedphase_1

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

NCT03516214
completedphase_1

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03333343Phase 1

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Active Not Recruiting
NCT03292133Phase 2

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Terminated
NCT02108964Phase 1

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Completed
NCT03516214Phase 1

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Completed
NCT02900664Phase 1

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Completed
NCT02323126Phase 2

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6